Filip Tudor

Dr. Filip Tudor

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DMDiana Maržić
Diana Maržić
BMBlažen Marijić
Blažen Marijić
TBTamara Braut
Tamara Braut
SJStefan Janik
Stefan Janik
MAManuela Avirović
Manuela Avirović
Boban M. ErovićBoban M. Erović
Boban M. Erović
Background: The aim of this study was to (i) determine IMP3 protein expression in benign and malignant laryngeal lesions, (ii) compare its expression to Ki-67, p53, cyclin D1, and (iii) finally, to examine the prognostic power of IMP3 in squamous cell carcinomas of the larynx (LSSC). Methods: IMP3 protein expression was evaluated in 145 patients, including 62 LSCC, 45 dysplasia (25 with low and 20 with high-grade dysplasia), and 38 benign lesions (vocal cord polyps and nodules). Results: IMP3 was significantly higher expressed in LSCC compared to dysplasia and benign lesions (p < 0.001; p < 0.001, respectively). Similarly, higher expression patterns were observed for Ki-67 and p53, whereas cyclin D1 was equally distributed in all three lesions. IMP3 (p = 0.04) and Ki-67 (p = 0.02) expressions were significantly linked to neck node positivity, and IMP3 overexpression to worse disease-specific survival (p = 0.027). Conclusion: Since IMP3 showed significantly higher expression in laryngeal carcinomas, but not in high- or low-grade dysplasia, it serves as a useful marker to differentiate between invasive and noninvasive lesions. Higher IMP3 expression represented a significantly worse prognosticator for clinical outcomes of patients with squamous cell carcinoma of the larynx.

25 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
FTFilip Tudor
Filip Tudor
BMBlažen Marijić
Blažen Marijić
EBEmina Babarovic
Emina Babarovic
IHIta Hadžisejdić
Ita Hadžisejdić
Background: Despite the considerable advancement in the field of medicine over recent decades, laryngeal cancer continues to be a challenge. The field of immune oncology has generated promising immunomodulation therapies and opened up new ways of treatment. Methods: Our retrospective study included 102 patients diagnosed with laryngeal squamous cell cancer (LSCC). Immunohistochemistry was used to evaluate the expression of PD-L1 and tumor microenvironment cells (CD4, CD8, CD68 and CD163). Results: PD-L1 expression showed statistically significant positive correlations with all examined tumor microenvironment cells. Patients with high CD68 and CD163 expression intratumorally (p = 0.0005 and p = 0.006, respectively) had statistically significant shorter disease-specific survival. Moreover, a statistically shorter time to recurrence was found in patients with high CD68 intratumoral and CD8 overall counts (p = 0.049 and p = 0.019, respectively). Also, high CD8 overall (>23%) and CD68 intratumoral (>2.7%) expression were statistically significant predictors of recurrence (p = 0.028, OR = 3.11 and p = 0.019, OR = 3.13, respectively). Conclusions: Higher CD68 and CD163 expression represented significantly worse prognosticators for clinical outcomes in patients with LSCC. In order to determine which LSCC patients will benefit from anti-PD-1/PD-L1 inhibitors, it is crucial to elucidate the relationship between PD-L1 expression, immune cell distribution and prognosis in LSCC patients.

Verified
Journal Article
Open access
PDF file
BMBlažen Marijić
Blažen Marijić
FTFilip Tudor
Filip Tudor
SJStefan Janik
Stefan Janik
SGStefan Grasl
Stefan Grasl
FFFlorian Frommlet
Florian Frommlet
Boban M. ErovićBoban M. Erović
Boban M. Erović
Purpose: We conducted an outcome analysis on surgically treated laryngeal squamous cell carcinoma (LSCC) patients. Methods: A multicenter retrospective study with 352 patients was analyzed. A new nomogram that incorporates age, T- and N-classification, and treatment was created. Results: Recurrence was observed in 65 (18.5%) patients after a mean time of 16.5 months. After 60 months, 91 (25.9%) of patients developed secondary primary tumors (SPT), most commonly in the lungs (n = 29; 8.2%) followed by other head and neck cancers (n = 21; 6.0%). Notably, the mean time to occurrence of secondary head and neck cancers was twice that of lung cancer (101.1 vs. 47.5 months). Conclusion: Recurrent disease is less common in LSCC patients and appears much earlier than SPT. Because one in every four laryngeal cancer patients develops SPTs within 5–10 years, long-term care and follow-up, including imaging studies, are highly recommended. The nomogram was useful for estimating survival.

21 March 2024 in Brazilian Journal of Otorhinolaryngology
Verified
Journal Article
Open access
FTFilip Tudor
Filip Tudor
Andro KošecAndro Košec
Andro Košec
APAlan Pegan
Alan Pegan

20 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SJStefan Janik
Stefan Janik
BMBlažen Marijić
Blažen Marijić
FTFilip Tudor
Filip Tudor
KEKatharina B. Erovic
Katharina B. Erovic
Boban M. ErovićBoban M. Erović
Boban M. Erović
Background/Objectives: Metastasizing pleomorphic adenoma (MPA) is a rare salivary gland tumor characterized by benign pleomorphic adenoma morphology despite regional or distant metastatic behavior. Because most evidence derives from case reports and small series, this systematic review and pooled case-report analysis aimed to summarize published patient-level data and to explore clinicopathologic features, metastatic distribution, treatment, and survival without inferring causal treatment effects. Methods: PubMed, Scopus, Google Scholar, and reference lists were searched for English-language reports published up to 1 August 2025. Eligible reports described primary pleomorphic adenoma and metastatic disease reported as MPA with benign morphology; carcinoma ex pleomorphic adenoma and other malignant pleomorphic adenoma variants were excluded. The primary pooled analysis was restricted to 122 published case-report patients. Institutional cases are presented separately as illustrative cases and were not included in the primary pooled statistical analyses. Unknown, not reported, NA, and unclear values were treated as missing, and denominators are reported. Because only 16 deaths were available, survival analyses were exploratory and no multivariable Cox model was fitted. No formal risk-of-bias or certainty-of-evidence assessment was performed. Results: In the 122 published patients, sex was available for 121 patients and 71/121 (58.7%) were female. Primary tumors most frequently arose in the parotid gland (92/122, 75.4%), followed by the submandibular gland (15/122, 12.3%) and palate/soft palate (10/122, 8.2%). The median interval between primary pleomorphic adenoma and MPA was 12 years (IQR 7–21; range 0–69; n = 118). Metastatic site was reported in 120 patients and was non-mutually exclusive: bone/skeleton and lymph nodes/neck were each reported in 42/120 patients (35.0%), followed by lung/pulmonary metastases in 31/120 (25.8%). Treatment information was available for 98/122 patients. MPA-directed surgery was performed in 86/98 patients with available treatment information (87.75%). The non-surgical cohort received radiotherapy, chemotherapy, palliative treatment, treatment refusal, observation, or other non-surgical strategies. A total of 72 patients had complete covariate data for the reported Cox analyses, including 16 deaths. Estimated 1- and 5-year overall survival were 89.97% and 66.2%, respectively. Surgery was associated with improved overall survival in exploratory Kaplan–Meier comparison (log-rank p = 0.008) and univariable Cox analysis (HR 0.119, 95% CI 0.018–0.810, p = 0.030), but this association should not be interpreted as causal. Conclusions: MPA remains difficult to predict and the available evidence is limited by case-report design, missing data, publication bias, and heterogeneous follow-up. Surgical management may be considered in selected patients when technically feasible and clinically appropriate, but the observed survival association is exploratory and may be influenced by selection bias and disease characteristics. Multicenter registries, standardized reporting, centralized pathology review, molecular characterization, and longer follow-up are needed.

Verified
Journal Article
Open access
PDF file
FTFilip Tudor
Filip Tudor
BMBlažen Marijić
Blažen Marijić
EBEmina Babarovic
Emina Babarovic
IHIta Hadžisejdić
Ita Hadžisejdić
Laryngeal dysplasia (LD) is the principal precursor of laryngeal squamous cell carcinoma (LSCC), but reliable biomarkers predicting malignant transformation remain unavailable. This study investigated programmed death-ligand 1 (PD-L1) expression and immune microenvironment remodeling during laryngeal carcinogenesis. Immunohistochemical analysis of PD-L1, CD4, CD8, CD68, and CD163 was performed in 36 benign lesions, 41 LDs, and 102 LSCCs. PD-L1 expression was assessed using the combined positive score (CPS) and tumor proportion score (TPS), while immune cell infiltration was quantified in the intraepithelial and stromal compartments and across the entire tissue specimen. PD-L1 expression and infiltration of all investigated immune cell populations increased progressively from benign lesions through dysplasia to invasive carcinoma. High-grade dysplasia exhibited significantly greater CD4 infiltration in all compartments and increased stromal CD8 and CD163 infiltration than low-grade dysplasia. PD-L1 expression positively correlated with intraepithelial CD163 and stromal CD8 infiltration. Although no biomarker independently distinguished progressive from non-progressive dysplasia, overall CD4, intraepithelial and overall CD68, and stromal CD163 were associated with progression risk. Immune microenvironment remodeling begins during the dysplastic stage of laryngeal carcinogenesis. These findings may improve risk stratification of laryngeal dysplasia and support the development of immunopreventive and immune-targeted therapeutic strategies.